Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Meng, Wenxia ^a   Xia, Qingjie ^b   Wu, Lanyan ^c   Chen, Sixiu ^a   He, Xin ^a   Zhang, Lin ^a   Gao, Qinghong ^c   Zhou, Hongmei ^c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; PROTEIN SERINE THREONINE KINASE; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADIPOSE TISSUE; ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUTH CARCINOMA; MYOFIBROBLAST; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; AGED; GENETICS; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 79952057276     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-88     Document Type: Article

References (24)

1. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005, 23:2078-2093. 10.1200/JCO.2005.02.047, 15774796.
2. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647. 10.1126/science.1071809, 12040180.
3. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998, 58:5329-5332.
4. Munoz-Antonia T, Muro-Cacho C, Sharma S, Cantor A, Bepler G. Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions. Cancer 2007, 110:1527-1531. 10.1002/cncr.22937, 17676583.
5. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007, 67:1090-1098. 10.1158/0008-5472.CAN-06-3117, 17283142.
6. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG. Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway. Clin Cancer Res 2008, 14:5722-5730. 10.1158/1078-0432.CCR-08-0546, 2844539, 18794080.
7. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002, 24:165-180. 10.1002/hed.10004, 11891947.
8. Mincione G, Di Marcantonio MC, Artese L, Vianale G, Piccirelli A, Piccirilli M, Perrotti V, Rubini C, Piattelli A, Muraro R. Loss of expression of TGF-ß1, TßRI, and TßRII correlates with differentiation in human oral squamous cell carcinomas. Int J Oncol 2008, 32(2):323-31.
9. Hui P, Shintaniy S, Kim Y, Wong DT. Loss of p12CDK2-AP1 Expression in human oral squamous cell carcinoma with disrupted transforming growth factor-β-Smad signaling pathway. Neoplasia 2006, 8:1028-1036. 10.1593/neo.06580, 1783720, 17217620.
10. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Current Opinion in Genetics & Development 2009, 19:67-73.
11. Kiaris H, Trimis G, Papavassiliou AG. Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy. Current Medicinal Chemistry 2008, 15:3062-3067. 10.2174/092986708786848596, 19075653.
12. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
13. Orimo A, Gupta PB, Sgrol DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348. 10.1016/j.cell.2005.02.034, 15882617.
14. Liu Y, Hu T, Shen J, Li SF, Lin JW, Zheng XH, Gao QH, Zhou HM. Separation, cultivation and biological characteristics of oral carcinoma-associated fibroblasts. Oral Dis 2006, 12:375-380. 10.1111/j.1601-0825.2005.01207.x, 16792722.
15. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337. 10.1038/nature03096, 15549095.
16. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 2007, 7:156. 10.1186/1471-2407-7-156, 1988827, 17692120.
17. Sousa AM, Liu T, Guevara O, Stevens J, Fanburg BL, Gaestel M, Toksoz D, Kayyali US. Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem 2007, 100:1581-1592. 10.1002/jcb.21154, 2586991, 17163490.
18. Gordon KJ, Mei D, Chislock EM, Field TA, Blobe GC. Loss of type III transforming growth factor b receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 2008, 29:252-262. 10.1093/carcin/bgm249, 17999987.
19. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2007, 117:206-217. 10.1172/JCI29293, 1679965, 17160136.
20. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008, 68:918-926. 10.1158/0008-5472.CAN-07-5714, 2519173, 18245495.
21. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45:S163-S175. 10.1016/j.lungcan.2004.07.977, 15552797.
22. Kang Y. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003, 11:915-926. 10.1016/S1097-2765(03)00109-6, 12718878.
23. Hempell N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the type III TGF-b receptor is negatively regulated by TGF-beta. Carcinogenesis 2008, 29:905-912. 10.1093/carcin/bgn049, 2902381, 18299279.
24. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20:4434-4439. 10.1200/JCO.2002.02.108, 12431965.